HYPERSEN
As a leader in chromatic confocal technology, Hypersen is pleased to release a Coaxial 3D Line Confocal Sensor (HPS-LCX1000) for the global measurement & inspection market. This sensor offers an effective and high-precision (0.1µm) 3D inspection solution to the measurement and defects detection problems in the fields of semiconductors, consumer electronics, new energy, metal, automobile, and aviation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115006199/en/
Hypersen releases a coaxial 3D line confocal sensor HPS-LCX1000 to tackle the difficulties in measurement and inspection of semiconductor wafer/chip, LED/OLED display, electronic components, metal, automotive and aerospace parts. It solves the shadowing problem when measuring targets with holes, steep slopes, and protruding components. (Photo: Business Wire)
Compared to current line confocal sensors, HPS-LCX1000 excels in its lateral resolution (1.1µm) and coaxial structure. Coaxial design means the incident and reflected rays overlap. Therefore, it solves the shadowing problem when measuring targets with holes, steep slopes, and protruding components.
In addition, it has the following advantages:
- High adaptability to various materials, especially transparent and highly reflective ones, mirrored surfaces, and even liquid
- Robust capability to measure complex geometric shapes
- Max. surface slope on mirror: ±45°
- Generate 2D image and 3D point cloud data by one scan
- Axial precision: 0.1µm
- Point density: 2,048 points/profile
- High scan speed: up to 35,000 lines/sec.
Separated sensor head and controller design greatly reduces the measurement error caused by heat generation of the sensor. Besides that, a 40G optical fiber enables low-latency data transmission between the sensor head and the controller. What’s more, the controller is equipped with an 8-core 64-bit CPU, high-speed FPGA and an AI accelerator. With integrated high efficient AI algorithm, HPS-LCX1000 reaches a scanning speed of 35,000 lines/sec. and enables real-time 3D point cloud data output.
What HPS-LCX1000 can do:
- 3D topography and dimension measurement
- Surface defects detection
- Curved surface measurement
- Displacement and roughness measurement
- Gap and flush measurement
- Thickness measurement of multi-layer transparent materials
Test engineers can find this sensor very helpful when conducting the following tasks:
- Wafer and PCB bumps 3D inspection
- Die defects detection
- IC chip pin 3D inspection
- Wire bonding defects detection
- Highly angled LED/OLED display profile measurement
- Smart watch components measurement
- Gluing effects inspection
- Automotive and aerospace components appearance inspection
About Hypersen Technologies:
Established in 2015, Hypersen manufactures and sells high-end optical and force torque sensors. As an innovative company in high-precision measurement field, Hypersen provides: 3D optical profilometer, 3D line confocal sensor, chromatic confocal sensor, high speed industrial camera, 3D LiDAR and 6-axis force torque sensor.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006199/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release
ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin
BoConcept, Lego, Lurpak, and Pandora are among the Honoured Winners of the 2025-2026 World Branding Awards in Osaka17.11.2025 11:48:00 CET | Press release
The 20th World Branding Awards celebrated the success and achievements of leading brands across National, Regional, and Global categories. In the 2025–2026 edition, over 1,092 brands from 66 countries were nominated as “Brand of the Year”. From this distinguished selection, fewer than 100 brands emerged as winners, representing the highest standards of excellence across the three tiers of recognition. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. Over 80 international guests joined the celebration, hosted by Allie Sakakibara and enriched by a keynote from Miho Noguchi on immersive brand experiences. Honoured as Global winners in branding across diverse industries were Cadbury (USA), IKEA (Sweden), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). Winners from Denmark include BoConcept, Lego, Lurpak, and Pandora.Other National tier winners incl
Global Winners of the 2025–2026 World Branding Awards Announced at First-Ever Japan Ceremony17.11.2025 11:43:00 CET | Press release
Now in its 20th edition, the World Branding Awards continues to spotlight the world’s most impactful and trusted brands. This year, over 1,092 brands from 66 countries were nominated as “Brand of the Year”, with less than 100 declared Winners across Global, Regional, and National tiers. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. The 2025–2026 edition welcomed over 80 international guests and was presented by the acclaimed Allie Sakakibara. The evening was further elevated by a keynote presentation from Miho Noguchi, who shared insights on building emotional resonance through immersive brand experiences. Global Tier winners celebrated their outstanding branding excellence across various industries, including IKEA (Sweden), Lurpak (Denmark), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). These brands consistently demonstrated strength, inf
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US17.11.2025 11:30:00 CET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.1 POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.2 "Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.3 “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds
WEX® Unlocks Access to 20,000+ Tesla Superchargers Across Europe17.11.2025 11:15:00 CET | Press release
EV drivers of any car brand using the EV Driver by WEX app can now charge at one of Europe’s largest and most reliable charging networks, benefitting from low-cost fast charging across 1,500+ locations. WEX® (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced integration with the Tesla Supercharger network, adding over 20,000 fast-charging points across 1,500+ locations to its platform. The move significantly expands charging options for WEX’s customers, particularly in areas where high-power charging has been limited or expensive. By bringing Tesla Superchargers into their ecosystem, WEX gives drivers access to competitively priced fast charging with speeds up to 250 kW, increasing availability of high-power charging stations by 10%. WEX customers already use the EV Driver by WEX app to charge at over 1 million charging points throughout Europe. Now, they can access Tesla Superchargers with the same seamless experience: compari
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom